Header Logo

Michael Gold

Concepts (433)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Uterine Cervical Neoplasms
44
2023
285
5.370
Why?
Papillomavirus Infections
21
2020
137
2.980
Why?
Cervical Intraepithelial Neoplasia
25
2020
80
2.810
Why?
Colposcopy
23
2020
61
2.230
Why?
Endometrial Neoplasms
15
2024
187
2.190
Why?
Ovarian Neoplasms
15
2023
567
1.480
Why?
Papillomaviridae
15
2020
85
1.350
Why?
Antineoplastic Combined Chemotherapy Protocols
9
2024
375
1.300
Why?
Female
108
2024
14663
1.290
Why?
Mass Screening
6
2019
149
1.260
Why?
Adult
67
2024
7507
1.190
Why?
Middle Aged
63
2024
6914
1.160
Why?
Aged
54
2024
5231
1.120
Why?
Uterine Cervical Dysplasia
5
2016
35
1.030
Why?
Cervix Uteri
9
2017
63
1.020
Why?
Aged, 80 and over
33
2024
1944
1.010
Why?
Lymph Nodes
7
2023
98
0.990
Why?
Urokinase-Type Plasminogen Activator
3
2012
11
0.960
Why?
Humans
111
2024
27169
0.940
Why?
Fallopian Tube Neoplasms
5
2013
49
0.910
Why?
Genital Neoplasms, Female
8
2013
61
0.870
Why?
Peptide Fragments
3
2012
200
0.850
Why?
Neoplasm Recurrence, Local
9
2024
312
0.850
Why?
Neoplasm Staging
22
2021
462
0.760
Why?
Precancerous Conditions
7
2020
33
0.730
Why?
Carcinoma, Squamous Cell
9
2012
155
0.730
Why?
Positron Emission Tomography Computed Tomography
2
2017
29
0.690
Why?
Squamous Intraepithelial Lesions of the Cervix
1
2019
1
0.650
Why?
Retrospective Studies
28
2019
2457
0.640
Why?
Adolescent
28
2021
2997
0.640
Why?
Immunocompromised Host
1
2019
27
0.640
Why?
Vulvar Neoplasms
5
2012
25
0.640
Why?
Biopsy
10
2019
202
0.630
Why?
Community Health Services
1
2019
32
0.630
Why?
Early Detection of Cancer
8
2020
122
0.620
Why?
Peritoneal Neoplasms
4
2013
76
0.620
Why?
Disease Management
1
2019
86
0.610
Why?
Young Adult
21
2021
2633
0.590
Why?
Contraceptive Agents, Female
4
2010
6
0.550
Why?
Retroperitoneal Neoplasms
1
2017
9
0.550
Why?
Conization
2
2007
11
0.540
Why?
Vaginal Smears
9
2018
44
0.540
Why?
Carcinoma in Situ
2
2013
44
0.510
Why?
Sensitivity and Specificity
14
2018
510
0.490
Why?
Survival Rate
10
2012
411
0.490
Why?
Carboplatin
6
2024
107
0.460
Why?
Cystadenocarcinoma, Serous
2
2007
31
0.450
Why?
Uterine Neoplasms
5
2017
70
0.440
Why?
Fluorodeoxyglucose F18
4
2017
26
0.430
Why?
Antineoplastic Agents
6
2013
660
0.420
Why?
Adenocarcinoma
7
2018
288
0.420
Why?
Lymphatic Metastasis
9
2017
119
0.420
Why?
Radiopharmaceuticals
4
2017
69
0.410
Why?
Risk Assessment
7
2018
598
0.410
Why?
Disease-Free Survival
9
2012
225
0.400
Why?
United States
12
2020
2063
0.390
Why?
Neoplasms, Glandular and Epithelial
1
2012
67
0.370
Why?
Paclitaxel
5
2024
184
0.350
Why?
Prospective Studies
8
2018
1221
0.350
Why?
Positron-Emission Tomography
2
2008
98
0.340
Why?
Papanicolaou Test
6
2018
24
0.340
Why?
Lymph Node Excision
11
2023
96
0.330
Why?
Chemotherapy, Adjuvant
6
2009
109
0.320
Why?
Biomarkers, Tumor
8
2014
377
0.320
Why?
Treatment Outcome
15
2013
2286
0.310
Why?
CA-125 Antigen
1
2008
19
0.310
Why?
Genotype
10
2018
444
0.290
Why?
Contraceptives, Oral, Hormonal
2
1999
9
0.290
Why?
Electrocoagulation
1
2007
20
0.290
Why?
Human papillomavirus 16
5
2018
23
0.280
Why?
Sarcoma, Endometrial Stromal
1
2007
3
0.280
Why?
Contraception Behavior
2
1998
16
0.270
Why?
Vaginal Neoplasms
3
2016
12
0.270
Why?
Pregnancy
6
2019
1154
0.250
Why?
DNA, Viral
4
2014
51
0.250
Why?
Neoplasm Grading
6
2017
104
0.230
Why?
Amifostine
1
2003
5
0.220
Why?
Topotecan
1
2003
12
0.220
Why?
Pregnancy in Adolescence
2
2001
29
0.220
Why?
Stress, Psychological
2
2010
211
0.220
Why?
Patient Selection
2
2008
143
0.220
Why?
Cross-Sectional Studies
5
2019
932
0.220
Why?
Contraceptives, Postcoital
2
2001
2
0.210
Why?
Combined Modality Therapy
5
2013
291
0.210
Why?
Neutropenia
1
2003
36
0.210
Why?
Physician's Role
1
2003
29
0.210
Why?
Risk Factors
11
2013
2038
0.200
Why?
Sentinel Lymph Node Biopsy
3
2012
16
0.200
Why?
Cancer Survivors
1
2023
39
0.200
Why?
Double-Blind Method
5
2024
405
0.200
Why?
Radiography
5
2012
201
0.200
Why?
Clinical Trials as Topic
1
2003
206
0.190
Why?
Contraception
1
2001
21
0.190
Why?
Disease Progression
7
2013
458
0.190
Why?
Reproducibility of Results
4
2017
751
0.180
Why?
Job Satisfaction
1
2001
24
0.180
Why?
Estradiol
1
2001
175
0.180
Why?
Obesity
3
2020
654
0.180
Why?
Fellowships and Scholarships
1
2001
38
0.180
Why?
Papillomavirus Vaccines
3
2010
53
0.180
Why?
Radiotherapy, Adjuvant
4
2008
60
0.170
Why?
Gynecology
1
2001
56
0.170
Why?
Molecular Diagnostic Techniques
2
2012
21
0.170
Why?
Inservice Training
1
2000
9
0.170
Why?
Taxoids
2
2012
36
0.170
Why?
Neoplasms, Unknown Primary
1
1999
8
0.170
Why?
Physical Education and Training
1
2000
45
0.170
Why?
Medical Oncology
1
2001
87
0.170
Why?
Medroxyprogesterone Acetate
3
2010
18
0.170
Why?
Military Personnel
1
2000
45
0.160
Why?
Progestins
2
1999
10
0.160
Why?
Vibrio
1
2019
4
0.160
Why?
Clustered Regularly Interspaced Short Palindromic Repeats
1
2019
14
0.160
Why?
Physicians
1
2020
81
0.160
Why?
Adaptation, Psychological
1
2000
118
0.160
Why?
Attitude of Health Personnel
1
2020
139
0.160
Why?
Cytodiagnosis
1
2018
12
0.160
Why?
Genome, Bacterial
1
2019
68
0.160
Why?
CRISPR-Cas Systems
1
2019
44
0.160
Why?
Vagina
2
2016
42
0.150
Why?
Organoplatinum Compounds
2
2008
23
0.150
Why?
Electrosurgery
5
2012
15
0.150
Why?
Dose-Response Relationship, Drug
4
2008
589
0.150
Why?
Surveys and Questionnaires
6
2012
934
0.150
Why?
Curettage
1
2017
4
0.150
Why?
African Americans
1
2020
350
0.150
Why?
Students
1
2000
191
0.140
Why?
Practice Guidelines as Topic
1
2019
235
0.140
Why?
Amenorrhea
1
1997
5
0.140
Why?
Fallopian Tubes
1
1997
14
0.140
Why?
Predictive Value of Tests
3
2008
472
0.140
Why?
Injections, Subcutaneous
2
2008
58
0.140
Why?
Ovary
1
1997
69
0.140
Why?
Oklahoma
7
2013
979
0.130
Why?
Age Factors
5
2010
726
0.130
Why?
Sexual Behavior
4
2012
87
0.130
Why?
Case Management
1
2016
11
0.130
Why?
Case-Control Studies
2
2008
707
0.130
Why?
Prognosis
3
2008
763
0.130
Why?
Specimen Handling
2
2013
30
0.130
Why?
Cohort Studies
6
2010
864
0.130
Why?
Laparoscopy
4
2002
143
0.130
Why?
Salvage Therapy
2
2007
32
0.130
Why?
Conversion Disorder
1
1995
2
0.120
Why?
Contraceptive Devices
1
1995
1
0.120
Why?
Levonorgestrel
1
1995
5
0.120
Why?
Health Knowledge, Attitudes, Practice
1
1998
284
0.120
Why?
Prevalence
3
2020
478
0.120
Why?
Personality Development
1
1994
6
0.120
Why?
Homosexuality, Female
1
1994
3
0.120
Why?
Homosexuality, Male
1
1994
16
0.120
Why?
Antibodies, Monoclonal, Humanized
3
2024
133
0.120
Why?
Microsatellite Instability
1
2014
10
0.110
Why?
Ki-67 Antigen
2
2012
23
0.110
Why?
Vulva
1
2013
5
0.110
Why?
Parenting
1
1994
56
0.110
Why?
Urine
1
2013
14
0.110
Why?
Bone Density
2
2010
99
0.110
Why?
Polyploidy
1
2013
12
0.110
Why?
Lymphocytes
1
2014
82
0.110
Why?
Insurance, Health, Reimbursement
1
2013
10
0.110
Why?
Niacinamide
1
2013
13
0.100
Why?
Genotyping Techniques
1
2012
20
0.100
Why?
Quality of Health Care
1
2013
78
0.100
Why?
Sterilization, Tubal
1
2012
6
0.100
Why?
Neoplasms, Squamous Cell
1
2012
5
0.100
Why?
Leiomyoma
1
2012
9
0.100
Why?
Cyclin-Dependent Kinase Inhibitor p16
1
2012
15
0.100
Why?
Protein-Tyrosine Kinases
1
2013
96
0.100
Why?
Placebos
2
2010
46
0.100
Why?
Menstruation
3
1998
9
0.100
Why?
Hyaluronan Receptors
1
2012
30
0.100
Why?
Indoles
1
2013
98
0.100
Why?
Viral Load
1
2012
31
0.100
Why?
Hysterectomy
4
2013
85
0.100
Why?
Genetic Heterogeneity
1
2012
30
0.100
Why?
Follow-Up Studies
6
2013
989
0.100
Why?
Cisplatin
3
2007
175
0.100
Why?
Protein Kinase Inhibitors
1
2013
143
0.100
Why?
Oncogene Proteins, Viral
3
2014
16
0.100
Why?
Drug Administration Schedule
4
2009
218
0.090
Why?
Medical History Taking
1
2011
20
0.090
Why?
Methylphenidate
1
2010
7
0.090
Why?
Central Nervous System Stimulants
1
2010
30
0.090
Why?
Pregnancy Complications, Neoplastic
1
2010
6
0.090
Why?
Bone Diseases, Metabolic
1
2010
8
0.090
Why?
Retinoids
2
2001
37
0.090
Why?
Fatigue
1
2010
63
0.080
Why?
Vitamin D Deficiency
1
2010
31
0.080
Why?
Referral and Consultation
3
2014
94
0.080
Why?
Pregnancy Outcome
1
2010
130
0.080
Why?
Receptors, Urokinase Plasminogen Activator
1
2008
11
0.080
Why?
Pelvis
3
2023
37
0.080
Why?
Fibrin Tissue Adhesive
1
2008
5
0.080
Why?
Incidence
4
2012
553
0.080
Why?
Lymphedema
1
2008
14
0.080
Why?
Peritoneum
1
2008
7
0.070
Why?
Neoplasm Metastasis
1
2008
150
0.070
Why?
Contraceptives, Oral
2
2012
23
0.070
Why?
Receptors, Cell Surface
1
2008
111
0.070
Why?
Catheters, Indwelling
2
2007
19
0.070
Why?
Postmenopause
1
2008
83
0.070
Why?
Bridged-Ring Compounds
1
2007
18
0.070
Why?
Vesicovaginal Fistula
1
2007
4
0.070
Why?
Carcinoma, Adenosquamous
1
2007
12
0.070
Why?
Immunohistochemistry
3
2014
455
0.070
Why?
Image Processing, Computer-Assisted
1
2008
247
0.070
Why?
Pilot Projects
3
2014
397
0.060
Why?
Preoperative Care
1
2006
76
0.060
Why?
Carcinosarcoma
1
2005
22
0.060
Why?
Metabolism
2
1995
9
0.060
Why?
Male
5
2020
13043
0.060
Why?
Human papillomavirus 18
2
2018
6
0.060
Why?
Spectrometry, Fluorescence
1
2004
63
0.060
Why?
Cystadenocarcinoma, Papillary
1
2003
5
0.060
Why?
Amino Acid Sequence
1
2005
679
0.060
Why?
Ambulatory Care
1
2003
58
0.050
Why?
Catheterization, Central Venous
1
2003
37
0.050
Why?
Molecular Sequence Data
1
2005
1041
0.050
Why?
Clinical Trials, Phase II as Topic
1
2003
23
0.050
Why?
Multicenter Studies as Topic
1
2003
43
0.050
Why?
Antigens, Viral
1
2003
23
0.050
Why?
Gene Expression Profiling
1
2005
440
0.050
Why?
Neoplasm Invasiveness
2
2014
180
0.050
Why?
Thallium
1
2002
2
0.050
Why?
Whole-Body Counting
1
2002
3
0.050
Why?
Iridium Radioisotopes
1
2002
3
0.050
Why?
ROC Curve
2
2013
140
0.050
Why?
Abdomen
1
2002
41
0.050
Why?
Life Style
1
2023
85
0.050
Why?
DNA
1
2004
365
0.050
Why?
Lipectomy
1
2001
2
0.050
Why?
Pregnancy, Unwanted
1
2001
1
0.050
Why?
Gynecologic Surgical Procedures
1
2001
33
0.050
Why?
Immunotherapy
1
2003
143
0.050
Why?
Uterine Cervical Diseases
2
2012
6
0.050
Why?
Thiourea
1
2001
17
0.050
Why?
Age Distribution
2
2012
70
0.050
Why?
Benzoates
1
2001
30
0.050
Why?
B7-H1 Antigen
1
2021
35
0.050
Why?
Cytoreduction Surgical Procedures
1
2021
31
0.050
Why?
Diet
1
2023
226
0.050
Why?
Patient Education as Topic
1
2001
87
0.050
Why?
Mentors
1
2001
31
0.040
Why?
Bevacizumab
1
2021
93
0.040
Why?
Neoadjuvant Therapy
1
2021
69
0.040
Why?
Africa South of the Sahara
1
2020
13
0.040
Why?
Carcinoma
1
2001
71
0.040
Why?
Career Choice
1
2001
52
0.040
Why?
Wit and Humor as Topic
1
2000
2
0.040
Why?
Anthropology, Cultural
1
2000
3
0.040
Why?
Observation
1
2000
5
0.040
Why?
Education, Medical, Graduate
1
2001
103
0.040
Why?
Relaxation Therapy
1
2000
5
0.040
Why?
Military Medicine
1
2000
3
0.040
Why?
Health Care Surveys
1
2020
67
0.040
Why?
Receptors, Retinoic Acid
1
1999
32
0.040
Why?
Bridged Bicyclo Compounds, Heterocyclic
1
1999
51
0.040
Why?
Fatal Outcome
1
1999
67
0.040
Why?
Contraindications
1
1999
13
0.040
Why?
Benzamides
1
1999
33
0.040
Why?
Logistic Models
2
2012
399
0.040
Why?
Self Concept
1
2000
52
0.040
Why?
Drug Prescriptions
1
1999
43
0.040
Why?
Gene Library
1
2019
45
0.040
Why?
Estrogens
1
1999
56
0.040
Why?
Chromosomes, Bacterial
1
2019
19
0.040
Why?
Culture Media
1
2019
97
0.040
Why?
Social Support
1
2000
123
0.040
Why?
Genetic Variation
1
2020
229
0.040
Why?
Gene Knockdown Techniques
1
2019
131
0.040
Why?
Longitudinal Studies
1
2000
404
0.040
Why?
Head and Neck Neoplasms
1
1999
84
0.040
Why?
Exercise
1
2023
469
0.040
Why?
Algorithms
2
2016
422
0.040
Why?
Genomics
1
2019
116
0.040
Why?
Brain Neoplasms
1
2001
298
0.040
Why?
Confidentiality
1
1998
10
0.040
Why?
Atypical Squamous Cells of the Cervix
1
2017
2
0.040
Why?
Phylogeny
1
2020
462
0.040
Why?
Proportional Hazards Models
2
2010
217
0.040
Why?
Tumor Virus Infections
1
1997
14
0.040
Why?
Probability
2
2010
75
0.040
Why?
Societies, Medical
1
2017
89
0.040
Why?
Weight Gain
1
1998
73
0.040
Why?
Endometrium
1
1997
38
0.040
Why?
Estrogen Replacement Therapy
1
1997
42
0.030
Why?
Human Papillomavirus DNA Tests
1
2016
1
0.030
Why?
Child
2
2010
2164
0.030
Why?
Transcription Factors
1
1999
512
0.030
Why?
Lung Neoplasms
1
1999
342
0.030
Why?
Condoms
1
1995
17
0.030
Why?
Menstrual Cycle
1
1995
23
0.030
Why?
Bacterial Proteins
1
2019
474
0.030
Why?
Psychosexual Development
1
1994
2
0.030
Why?
Adolescent Behavior
1
1995
67
0.030
Why?
Host-Pathogen Interactions
1
2014
89
0.030
Why?
Immunophenotyping
1
2014
59
0.030
Why?
DNA Helicases
1
2014
51
0.030
Why?
Chromosomes, Human, Pair 7
1
2013
12
0.030
Why?
Chromosomes, Human, Pair 20
1
2013
5
0.030
Why?
Chromosomes, Human, Pair 5
1
2013
10
0.030
Why?
Chromosomes, Human, Pair 3
1
2013
17
0.030
Why?
Models, Biological
2
2009
448
0.030
Why?
In Situ Hybridization, Fluorescence
1
2013
72
0.030
Why?
Glial Cell Line-Derived Neurotrophic Factor
1
2013
3
0.030
Why?
Area Under Curve
1
2013
94
0.030
Why?
Ablation Techniques
1
2013
12
0.030
Why?
DNA, Neoplasm
1
2013
33
0.030
Why?
Lymphoscintigraphy
1
2012
2
0.030
Why?
Gene Expression Regulation, Neoplastic
2
2009
446
0.030
Why?
Oligonucleotides
1
2013
27
0.030
Why?
Health Care Costs
1
2013
49
0.030
Why?
Groin
1
2012
3
0.030
Why?
Myometrium
1
2012
7
0.030
Why?
Parity
1
2012
49
0.030
Why?
Brachytherapy
2
2003
50
0.020
Why?
Laser Capture Microdissection
1
2012
8
0.020
Why?
Angiogenesis Inhibitors
1
2013
104
0.020
Why?
Cell Transformation, Neoplastic
1
2012
114
0.020
Why?
Vascular Endothelial Growth Factor A
1
2013
177
0.020
Why?
Polymerase Chain Reaction
1
2012
262
0.020
Why?
Ultrasonography
1
2012
229
0.020
Why?
Postoperative Complications
2
2008
606
0.020
Why?
Drug Implants
1
2010
14
0.020
Why?
Biopsy, Needle
1
2010
47
0.020
Why?
Parathyroid Hormone
1
2010
23
0.020
Why?
Drug Screening Assays, Antitumor
2
2001
102
0.020
Why?
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
1
2010
1
0.020
Why?
Vaccines, Virosome
1
2010
1
0.020
Why?
Severity of Illness Index
1
2012
447
0.020
Why?
Chi-Square Distribution
1
2010
144
0.020
Why?
Prenatal Care
1
2010
40
0.020
Why?
Product Surveillance, Postmarketing
1
2010
12
0.020
Why?
Academic Medical Centers
1
2010
73
0.020
Why?
Vitamin D
1
2010
48
0.020
Why?
Affect
1
2010
82
0.020
Why?
Receptor, ErbB-3
1
2009
1
0.020
Why?
Fever
1
2010
31
0.020
Why?
Headache
1
2010
31
0.020
Why?
Psychiatric Status Rating Scales
1
2010
95
0.020
Why?
Frozen Sections
1
2009
4
0.020
Why?
Tumor Cells, Cultured
2
2001
310
0.020
Why?
Gestational Age
1
2010
141
0.020
Why?
Receptor, ErbB-2
1
2009
32
0.020
Why?
Multivariate Analysis
1
2010
300
0.020
Why?
Karnofsky Performance Status
1
2009
15
0.020
Why?
Deoxycytidine
1
2009
63
0.020
Why?
Recurrence
1
2010
317
0.020
Why?
Genes, Viral
1
2009
9
0.020
Why?
Creatinine
1
2009
57
0.020
Why?
Drug-Related Side Effects and Adverse Reactions
1
2010
66
0.020
Why?
Risk
1
2009
133
0.020
Why?
Women
1
2008
12
0.020
Why?
Smoking
1
2012
466
0.020
Why?
Automation
1
2008
19
0.020
Why?
Weight Loss
1
2009
73
0.020
Why?
Sutures
1
2008
15
0.020
Why?
Medical Records
1
2008
49
0.020
Why?
Infusions, Parenteral
1
2007
34
0.020
Why?
Antibodies, Monoclonal
1
2009
318
0.020
Why?
Magnetic Resonance Imaging
1
2012
812
0.020
Why?
RNA, Messenger
1
2009
648
0.020
Why?
Patient Compliance
1
2007
75
0.020
Why?
Pain
1
2010
254
0.020
Why?
Software
1
2008
121
0.020
Why?
Quality of Life
1
2010
468
0.020
Why?
Ifosfamide
1
2005
9
0.020
Why?
Body Mass Index
1
2007
389
0.020
Why?
Doxorubicin
1
2005
74
0.020
Why?
Artifacts
1
2005
50
0.010
Why?
Oligonucleotide Array Sequence Analysis
1
2005
190
0.010
Why?
Lymphatic System
1
2004
11
0.010
Why?
Psychopathology
1
1964
5
0.010
Why?
Social Conditions
1
1964
5
0.010
Why?
Breast Diseases
1
1964
7
0.010
Why?
Classification
1
1964
15
0.010
Why?
Fiber Optic Technology
1
2004
14
0.010
Why?
Injections, Intramuscular
1
2004
22
0.010
Why?
Drug Combinations
1
2004
50
0.010
Why?
Subclavian Vein
1
2003
4
0.010
Why?
Fear
1
1964
58
0.010
Why?
Equipment Failure
1
2003
31
0.010
Why?
Physical Examination
1
1964
53
0.010
Why?
Reference Values
1
2004
199
0.010
Why?
Viral Proteins
1
2004
62
0.010
Why?
Health Education
1
1964
71
0.010
Why?
Virion
1
2003
6
0.010
Why?
Capsules
1
2003
7
0.010
Why?
Plasminogen
1
2003
8
0.010
Why?
Palliative Care
1
1964
79
0.010
Why?
Papillomavirus E7 Proteins
1
2003
7
0.010
Why?
Anxiety
1
1964
140
0.010
Why?
Physician-Patient Relations
1
1964
112
0.010
Why?
Particle Size
1
2003
96
0.010
Why?
Plasmids
1
2003
122
0.010
Why?
Antibody Specificity
1
2003
114
0.010
Why?
Antibodies, Viral
1
2003
74
0.010
Why?
Metabolic Clearance Rate
1
2002
18
0.010
Why?
Intestinal Obstruction
1
2002
9
0.010
Why?
Radionuclide Imaging
1
2002
56
0.010
Why?
Radiation Protection
1
2002
17
0.010
Why?
Aorta, Abdominal
1
2002
15
0.010
Why?
Hysterectomy, Vaginal
1
2001
4
0.010
Why?
Meta-Analysis as Topic
1
2001
32
0.010
Why?
Fenretinide
1
2001
4
0.010
Why?
T-Lymphocytes
1
2003
279
0.010
Why?
Myocardium
1
2002
179
0.010
Why?
In Situ Nick-End Labeling
1
2001
42
0.010
Why?
Aorta, Thoracic
1
2001
49
0.010
Why?
Statistics, Nonparametric
1
2001
80
0.010
Why?
Mucin-1
1
2001
36
0.010
Why?
Analysis of Variance
1
2001
389
0.010
Why?
Feasibility Studies
1
2001
191
0.010
Why?
Length of Stay
1
2001
216
0.010
Why?
Retinoic Acid Receptor alpha
1
1999
5
0.010
Why?
Retinoid X Receptors
1
1999
24
0.010
Why?
Transcription Factor AP-1
1
1999
26
0.010
Why?
Neoplasm Transplantation
1
1999
88
0.010
Why?
Cell Division
1
1999
154
0.010
Why?
DNA-Binding Proteins
1
2003
481
0.010
Why?
Structure-Activity Relationship
1
1999
204
0.010
Why?
Phenotype
1
2001
668
0.010
Why?
Mice, Nude
1
1999
313
0.010
Why?
Breast Neoplasms
1
1964
448
0.010
Why?
Transcription, Genetic
1
1999
401
0.010
Why?
Metaplasia
1
1997
4
0.010
Why?
In Situ Hybridization
1
1997
33
0.010
Why?
Apoptosis
1
2001
740
0.010
Why?
Epithelium
1
1997
39
0.010
Why?
Neoplasms
1
1964
768
0.010
Why?
Mice
1
1999
4478
0.010
Why?
Animals
1
1999
10093
0.000
Why?
Gold's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (433)
Explore
_
Co-Authors (12)
Explore
_
Similar People (59)
Explore
_
Same Department Expand Description
Explore
_
Physical Neighbors
_